Serious Event

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Serious Event

Serious Adverse Events (SAEs) are adverse events that result in death, are life-threatening, require or prolong hospitalization, cause persistent or significant disability/incapacity, or are congenital anomalies/birth defects. Each serious event is categorized by term, organ system, assessment type, and source vocabulary to provide standardized reporting across clinical trials.

Serious Event path is as follows:

Study -> Results Section -> Adverse Events Module -> Serious Event

Study -> Results Section -> Adverse Events Module -> Serious Event -> Serious Event Stats

Serious Event

Ignite Creation Date: 2025-12-24 @ 9:30 PM
Ignite Modification Date: 2025-12-25 @ 7:15 PM
NCT ID: NCT05103332
Term: Aspartate aminotransferase increased
Organ System: Investigations
Assessment Type: SYSTEMATIC_ASSESSMENT
Source Vocabulary: MedDRA26.0
Notes: None
Study: NCT05103332
Study Brief: Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
Serious Event Stats (If Any):

Serious Event Stats

Group ID # Events # Affected # At Risk View
EG000 None 0 127 View
EG001 None 0 238 View
EG002 None 0 293 View
EG003 None 0 64 View
EG004 None 0 63 View
EG005 None 0 120 View
EG006 None 0 118 View
EG007 None 0 145 View
EG008 None 0 148 View
EG009 None 0 26 View
EG010 None 0 63 View
EG011 None 1 48 View
EG012 None 0 118 View
EG013 None 0 66 View
EG014 None 0 148 View
EG015 None 0 38 View
EG016 None 0 89 View
EG017 None 0 72 View
EG018 None 0 166 View
EG019 None 0 79 View
EG020 None 0 214 View